Novartis Projects $10B Windfall from Kisqali, Charts Path to 2030

Post by : Bianca Suleiman

Swiss pharmaceutical leader Novartis has unveiled an ambitious growth plan for the next decade, predicting annual sales increases of 5% to 6% on a currency-adjusted basis through 2030. This optimistic forecast hinges on the robust performance of its cancer treatments, Kisqali and Scemblix, both of which are now expected to achieve peak sales significantly higher than previous forecasts.

Cancer Therapies Leading the Charge

Novartis now anticipates that Kisqali, its treatment for breast cancer, will secure peak sales of at least $10 billion—up from an earlier estimate of $8 billion. Similarly, the leukemia medication Scemblix is on track to surpass its initial target, now predicted to hit a peak of $4 billion in sales, compared to the previous $3 billion forecast. Collectively, these drugs generated $4.4 billion in sales in the first three quarters of 2025, highlighting their significant contribution to Novartis’ financial portfolio. Analysts see potential for these estimates to rise even further.

In addition to Kisqali and Scemblix, Novartis has identified eight additional promising drugs with peak sales capacity between $3 billion and $10 billion, indicating a strong revenue pipeline in the medium to long term.

Focused Investment and Acquisitions

As it prepares for impending patent expirations on key products, including Entresto (for heart disease) and Xolair (for asthma), Novartis has committed $30 billion in acquisitions and licensing agreements this year. A notable transaction in this strategy is the $12 billion acquisition of Avidity Biosciences, which is expected to enhance Novartis’ pipeline with new treatment options for muscle disorders and raise projected annual sales growth to 6% for the 2024-2029 period.

Profit Margin and Operational Goals

Novartis is targeting a core operating income margin of at least 40% by 2029, with a modest 1-2 percentage point reduction anticipated from the Avidity acquisition, set to conclude in the first half of 2026. For context, the company recorded a margin of 41.2% during the first nine months of 2025. Third-quarter earnings met expectations, but margins fell short, as growth from new drugs did not completely offset declines in legacy products.

Future Vision and Potential Developments

The effectiveness of upcoming therapies, including the new skin disease medication Rhapsido, will be critical for Novartis to maintain its growth trajectory past 2030. Additionally, the pricing strategy for Kisqali in the U.S. under the Inflation Reduction Act in 2027 is projected to have only a minimal impact in its first year, according to company estimates.

With a promising pipeline in place, focused acquisitions, and innovative therapies on the rise, Novartis is strategically positioning itself to achieve steady growth despite challenges presented by patent expirations and market pressures.